CRBU · XBRL financial data

Caribou Biosciences financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CRBU's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	9,598	13,851	34,477	9,994	11,159
Research and development	52,255	82,230	112,075	130,153	109,439
General and administrative	24,322	38,020	38,461	46,457	37,914
Total operating expenses	76,577	120,250	150,536	176,610	159,503
Operating income (loss)	(66,979)	(106,399)	(116,059)	(166,616)	(148,344)
Interest expense	8	—	—	—	—
Income tax expense (benefit)	321	70	193	(9)	(550)
Net income (loss)	(66,923)	(99,421)	(102,070)	(149,105)	(148,125)
Earnings per share, basic USD per share	(2.11)	(1.64)	(1.38)	(1.65)	(1.59)
Earnings per share, diluted USD per share	(2.11)	(1.64)	(1.38)	(1.65)	(1.59)
Weighted average shares, basic thousands of shares	31,663	60,801	73,808	90,318	93,389
Weighted average shares, diluted thousands of shares	31,663	60,801	73,808	90,318	93,389

Fiscal years (CRBU's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	240,420	58,338	51,162	16,293	12,360
Marketable securities	135,412	189,325	277,665	193,244	126,980
Marketable securities, non-current	37,676	69,373	43,577	39,849	3,505
Accounts receivable	1,153	202	148	265	69
Prepaid and other current assets	7,236	7,921	6,155	6,589	2,913
Total current assets	391,192	260,248	338,841	219,377	145,232
Property and equipment, net	4,887	10,678	18,270	19,281	6,760
Right-of-use asset	0	24,230	22,182	20,009	17,670
Total assets	442,356	373,765	432,209	313,313	175,367
Accounts payable	3,990	1,146	3,120	2,476	5,783
Accrued liabilities	13,136	16,079	21,135	23,620	16,535
Total current liabilities	25,829	28,128	28,302	30,651	25,414
Lease liability, non-current	0	26,780	25,908	25,061	26,026
Total liabilities	54,531	72,894	63,808	60,362	53,192
Accumulated deficit	(97,794)	(197,215)	(299,285)	(448,390)	(596,515)
Total stockholders' equity	387,825	300,871	368,401	252,951	122,175
Total liabilities and equity	442,356	373,765	432,209	313,313	175,367
Common shares outstanding (cover page) thousands of shares	60,664	61,300	90,315	93,005	96,637

Fiscal years (CRBU's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(66,923)	(99,421)	(102,070)	(149,105)	(148,125)
Stock-based compensation	3,449	11,716	13,750	16,706	12,680
Depreciation and amortization	984	1,622	3,525	3,927	3,645
Net cash from operating activities	(32,519)	(90,966)	(93,291)	(138,200)	(110,992)
Purchases of property and equipment	2,121	6,454	11,613	4,880	1,359
Net cash from investing activities	(176,397)	(93,249)	(68,183)	86,607	102,238
Proceeds from issuing common stock	—	0	1,007	15,192	4,070
Net cash from financing activities	433,429	2,133	154,298	16,724	4,821
Net change in cash	224,513	(182,082)	(7,176)	(34,869)	(3,933)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Caribou Biosciences	26,194	1,499	(22,787)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17,076	not reported	(15,389)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	32,429	2,082	(23,400)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026
Protalix BioTherapeutics	27,420	19,896	(10,400)*	80.6M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
Alector	59,915	3,320	(34,217)*	111.7M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.